Navigation Links
VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
Date:9/9/2008

SAN FRANCISCO, Sept. 9 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will host a science briefing on Tuesday, September 16, 2008 at 12:00pm Eastern Time in New York City. Keynote speaker Dr. Peter Libby, Chief of Cardiovascular Medicine at the Brigham and Women's Hospital and Mallinckrodt Professor of Medicine at Harvard Medical School, will present "Inflammation in Atherosclerosis: Theory and Practice." Following Dr. Libby's presentation, Dr. Lawrence K. Cohen, chief executive officer of VIA Pharmaceuticals, will moderate an expert panel.

"We are pleased to have Dr. Libby speak about the importance of inflammation in atherosclerosis," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals. "While there are a number of currently available therapies that help reduce risk factors of heart disease, they do not address inflammation, an underlying cause of atherosclerosis and complications such as heart attack and stroke."

Dr. Libby is the Chief of Cardiovascular Medicine at the Brigham and Women's Hospital in Boston, Massachusetts and serves as the Mallinckrodt Professor of Medicine at Harvard Medical School. He also directs the D.W. Reynolds Cardiovascular Clinical Research Center at Harvard. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has received numerous awards and recognitions for his research accomplishments. His areas of clinical expertise include general and preventive cardiology. Dr. Libby writes a cardiovascular blog, "Consults-Experts on the Front Lines of Medicine", for
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Kennedy Joins with State Biotech Leaders to ... Research and Development while Boosting Rhode Island,s ... ,, PROVIDENCE, R.I., Dec. 14 ... in research, medicine and biotechnology gathered today ... discuss the importance of medical innovation in ...
(Date:12/14/2009)... 14 Boston Scientific Corporation (NYSE: ... offering of $2 billion aggregate principal amount of its ... The public offering consists of $850 million of 4.50 ... percent notes due January 2020 and $300 million of ... plans to use the net proceeds for general corporate ...
(Date:12/14/2009)... Calif., Dec. 14 Nektar Therapeutics (Nasdaq: ... has been appointed to serve on its board ... industry leader with over 35 years of experience ... "Dennis brings to Nektar extensive industry perspective at ... Howard W. Robin, President and CEO of Nektar ...
(Date:12/14/2009)... a US-based thermoforming company, has completed the delivery of Brookfield ... metal to a plastic enclosure with a smaller footprint and ... ... MA (PRWEB) December 14, 2009 -- ThermoFab, a US-based thermoforming ... Tester – helping Brookfield move from sheet metal to a ...
Breaking Biology Technology:Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2
... WellGen, Inc., a,biotechnology company using nutrigenomics to ... announced the appointment of,Robert M. Hellauer as Chief ... WellGen with over thirty years of broad,financial leadership ... joining WellGen, he spent six years in private ...
... Prostate, Lung and Brain Tumor ... Treatment, ... global leader in the field of radiosurgery,today announced key clinical presentation highlights ... in,Scottsdale, Ariz., At this year,s CyberKnife Users, meeting eight presentations reported,on ...
... Biosystems,Inc. (OTC Bulletin Board: WGBS), a leading developer ... cell research systems,today announced that Mr. Alnoor Shivji, ... presentation at the Roth Capital Partners,20th Annual OC ... 18-21, 2008, at the Ritz-Carlton Laguna Niguel in ...
Other Biology Technology:CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends 2CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends 3CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends 4WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference 2
(Date:12/11/2009)... studying how bacteria under stress collectively weigh and initiate ... into how humans make strategic decisions that affect their ... , Their study, published this week in the early ... National Academy of Sciences , was accomplished when the ... describe the complex interplay of genes and proteins that ...
(Date:12/11/2009)... . , Montreal, December 11, 2009 ... prevents cancer. In the December 11 edition of the ... Universit de Montral and the Universit de Sherbrooke explain ... cancer-causing activity of cytokines, hormones that are culprits in ... and people exposed to asbestos. , "Excessive cytokine ...
(Date:12/11/2009)... growers, profits have traditionally been limited by ... growing seasons can be short. Thanks to ... are being introduced that offer growers the ... in economic bonuses for both producers and ... of blackberry called "primocane-fruiting", which bear fruit ...
Breaking Biology News(10 mins):Bacteria provide new insights into human decision making 2Bacteria provide new insights into human decision making 3Bacteria provide new insights into human decision making 4Bacteria provide new insights into human decision making 5Scientists identify natural anti-cancer defenses 2New management methods extend blackberry season 2Florida Couple Creates National Emblem to Champion Health Care Reform 59144 1Florida Couple Creates National Emblem to Champion Health Care Reform 59144 2Sysmex America Names National Sales Director 59139 1Sysmex America Names National Sales Director 59139 2Grocery Produce Fighting for a Cause Wholly Pink Guacamole 14395 1Grocery Produce Fighting for a Cause Wholly Pink Guacamole 14395 2
... the degenerative inflammatory bone disease, may be a sign of ... the Annals of the Rheumatic Diseases. , The authors base ... between 30 and 79. Most of them were female twins. ... to check for signs of osteoarthritis and a blood sample ...
... of Virology and Immunology (GIVI) have identified a previously unknown ... a finding that may lead to new approaches for controlling ... 2, 2006, in Proceedings of the National Academy of Sciences, ... of GIVI Director Warner C. Greene, MD, PhD, explains why ...
... paramedics, doctors, and nurses follow standardized protocols for what to ... a full recovery. That's not the case if you have ... within a few hours and is often not diagnosed until ... research consortium, called Protocolized Care for Early Septic Shock (ProCESS), ...
Other Biology News:Osteoarthritis may be sign of faster 'biological ageing' 2Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G 2New study aims to stop sepsis in its tracks 2New study aims to stop sepsis in its tracks 3
... Polyclonal Antibody Description: ... polyclonal antibody. Detects 70 kDa YAP ... blotting and immunohistochemistry. ... Storage: -20C ...
...
... Mammalian Protein Extraction Reagent is ... solution that means no scraping, ... sonication! With M-PER Reagent, rapid ... minutes at room temperature, yielding ...
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
Biology Products: